Abstract 519P
Background
The phase Ⅲ CASPIAN study established durvalumab (D) plus etoposide with cisplatin or carboplatin (EP) as first-line standard of care (1L SoC) of ES-SCLC. The multicenter, single-arm, phase Ⅲb ORIENTAL study evaluated 1L D+EP in a large, real-world-like patient (pt) cohort in China. Preliminary safety and efficacy results were consistent with CASPIAN. Here we report final results and subgroup analysis.
Methods
Treatment-naïve ES-SCLC pts ≥18 years old with ECOG PS 0–2 received D 1500 mg + EP intravenously every 3 weeks for 4–6 cycles, followed by D monotherapy every 4 weeks until progressive disease or intolerable toxicity. Primary endpoints were immune-mediated adverse events (imAEs) and grade ≥3 AEs. Secondary endpoints included OS, PFS, and tumor response.
Results
166 pts from 32 sites were enrolled by Aug 2021 and 165 received study treatment (median [m] age 65 years; 140 [84.8%] male). At baseline, 6 (3.6%) were ECOG PS 2, 155 (93.9%) were stage Ⅳ, 21 (12.7%) had brain metastases, and 44 (26.7%) had liver metastases. By data cut-off (31 Mar 2023), median cycle number of D was 7 (range 1–25). 92 (55.8%) started subsequent systemic anticancer therapy. 40 (24.2%) reported imAEs (most common [≥5%]: hyperthyroidism [6.1%] and hypothyroidism [6.1%]; grade 1/2 mostly). Grade ≥3 AEs occurred in 82 (49.7%) pts and led to treatment interruption in 24 (14.5%). mOS was 14.8 months (mo) (m follow-up [mFU] 20.5 mo). 118 (71.5%) pts received D maintenance, with mOS of 16.6 mo. 85 (51.5%) pts received >4 EP cycles, with mOS of 17.4 mo (Table). mPFS was 6.3 mo (mFU 8.6 mo). ORR was 76.4%, with 3 (1.8%) complete responses (RECIST 1.1). Table: 519P
N=165 | 95% CI | ||
Any-cause AEs, n (%) | 161 (97.6) | ||
Grade ≥3 AEs, n (%) | 82 (49.7) | ||
imAEs, n (%) | 40 (24.2) | ||
Grade ≥3 imAEs, n (%) | 11 (6.7) | ||
mOS, mo | 14.8 | 13.2–16.0 | |
12-mo OS, % | 60.8 | 52.8–67.9 | |
24-mo OS, % | 26.2 | 17.5–35.6 | |
mPFS, mo | 6.3 | 5.6–6.5 | |
12-mo PFS, % | 17.6 | 12.0–24.1 | |
ORR, % | 76.4 | 69.1–82.6 | |
DCR, % | 89.1 | 83.3–93.4 | |
mDoR, mo | 5.1 | 4.7–5.7 | |
Subgroup analysis | n | mOS, mo | 95% CI |
Received D maintenance | 118 | 16.6 | 15.1–18.8 |
ECOG PS | |||
0–1 | 159 | 15.1 | 13.3–16.1 |
2 | 6 | 9.2 | 6.4–Not Available |
Number of EP cycles | |||
≤4 | 80 | 12.7 | 9.4–15.1 |
>4 | 85 | 17.4 | 14.0–21.7 |
First-line platinum | |||
Cisplatin | 17 | 11.1 | 6.5–18.8 |
Carboplatin | 148 | 15.2 | 13.3–16.6 |
Brain metastases | |||
With | 21 | 11.1 | 8.5–14.3 |
Without | 144 | 15.3 | 13.3–17.4 |
Liver metastases | |||
With | 44 | 9.6 | 6.5–13.2 |
Without | 121 | 16.1 | 14.3–18.2 |
Conclusions
Final results of ORIENTAL showed in the largest to date, real-world-like Chinese ES-SCLC cohort that D+EP was effective and well tolerated, further supporting D+EP as 1L SoC in China.
Clinical trial identification
NCT04449861.
Editorial acknowledgement
Medical writing support for the development of the abstract, under the input and direction of the authors, was provided by Xiaowei Ning and Bo Lyu from Costello Medical Singapore and funded by AstraZeneca China.
Legal entity responsible for the study
AstraZeneca China.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract